Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

16.36 -0.67 (-3.95%)
Streaming Delayed Price Updated: 10:50 AM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves
Acadia may experience a profit-taking pullback near-term but the recent high volume gapper and promising pipeline developments bode well for long-term uptrend. 
Via MarketBeat
Nasdaq Drops 50 Points; Wells Fargo Earnings Beat Views
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Friday. The Dow traded up 0.30% to 34,498.91 while the NASDAQ fell 0.36% to 14,087. The S&P... 
Via Benzinga
Why Acadia Pharmaceuticals Stock Is Soaring Today
Investors are cheering Acadia's latest news. 
Via The Motley Fool
Where ACADIA Pharmaceuticals Stands With Analysts
Via Benzinga
11 Analysts Have This to Say About ACADIA Pharmaceuticals
Via Benzinga
Reassuring Market Adoption of Daybue Fuels Acadia's Strategic Advancements, Analysts Boost Price Targets
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American  
Via Benzinga
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement. 
Via Benzinga
Crude Oil Down 2%; Citigroup Profit Tops Estimates
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Friday. The Dow traded up 0.31% to 34,501.62 while the NASDAQ rose 0.36% to 14,188.86. The S&P 500, also... 
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High
The company also expanded its commercial rights to the drug and added another to its line-up. 
Via Investor's Business Daily
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Are Acadia Pharmaceuticals Shares Trading Higher Today?
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher after the company expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American  
Via Benzinga
Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday. 
Via Benzinga
Microsoft To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Friday
Keybanc boosted the price target for Spotify Technology S.A. (NYSE: SPOT) from $180 to $205. Keybanc analyst Justin Patterson maintained an Overweight rating. Spotify shares rose 0.9% to $172.68 in... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Why These 2 Biotech Stocks Made Big Moves Late Thursday
Markets kept powering higher on the day. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst
Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false... 
Via Benzinga
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Penny Stocks That Could Skyrocket in the Next 12 Months
Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors. 
Via InvestorPlace
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.